No Data
Individual Investors Who Hold 45% of Peijia Medical Limited (HKG:9996) Gained 18%, Institutions Profited as Well
Peijia Medical Sees Up to 43% Jump in 2024 Revenue
PEIJIA-B (09996.HK) expected revenue for 2024 is approximately 0.61 billion yuan to -0.63 billion yuan, a year-on-year growth of about 38.3%-42.8%.
Gelonghui reported on February 10 that PEIJIA-B (09996.HK) announced that for the year ending December 31, 2024, the company's revenue is expected to be approximately 0.61 billion to 0.63 billion yuan, representing a year-on-year growth of about 38.3% to 42.8%. The strong revenue growth is mainly attributed to: (i) the continuous rapid growth of all neurointerventional product lines of the group; and (ii) the group's expanded market share in China's transcatheter aortic valve replacement ("TAVR") market. During the reporting period, the increase in surgical penetration rates, winning bids in volume-based procurement, and its comprehensive product pipeline and effective marketing contributed significantly.
Express News | Peijia Medical Sees FY Revenue Between RMB610.0 Mln and RMB630.0 Mln
AI hotspots continue to boost! Most Medical stocks in Hong Kong strengthen, with Micro-invasion Siasun Robot&Automation rising over 20%.
How does Sister Wood perceive this hot topic of AI Medical? What positive impacts will the emergence of DeepSeek bring to the medical field?
CITIC: Raised the Target Price of PEIJIA-B (09996) to 5 Hong Kong dollars, maintaining an "outperform industry" rating.
PEIJIA-B's rich product matrix helps respond to subsequent changes in the competitive landscape, and the company may continue to maintain its top position in the valve market.
Peijia Medical Limited's (HKG:9996) 29% Share Price Plunge Could Signal Some Risk
